{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:55:13Z","timestamp":1761897313012,"version":"build-2065373602"},"reference-count":7,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.reuma.2020.06.003","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T04:11:57Z","timestamp":1592367117000},"page":"559-561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Anakinra, una alternativa potencial en el tratamiento de la infecci\u00f3n respiratoria grave por SARS-CoV-2 refractaria a tocilizumab"],"prefix":"10.1016","volume":"17","author":[{"given":"Luis","family":"Figuero-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Olivares-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto A.","family":"Escala-Cornejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Ter\u00e1n-Brage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"L\u00f3pez-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J.","family":"Cruz-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2020.06.003_bib0040","doi-asserted-by":"crossref","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.reuma.2020.06.003_bib0045","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-Cov-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.reuma.2020.06.003_bib0050","article-title":"IV anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of COVID19","volume":"2","author":"Wampler Muskardin","year":"2020","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.reuma.2020.06.003_bib0055","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12967-020-02339-3","article-title":"Why tocilizumab could be an effective treatment for severe COVID-19?","volume":"18","author":"Binqing Fu","year":"2020","journal-title":"J Transl Med."},{"key":"10.1016\/j.reuma.2020.06.003_bib0060","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe of life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist."},{"key":"10.1016\/j.reuma.2020.06.003_bib0065","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3899\/jrheum.200334","article-title":"The rheumatologist's role in COVID-19","volume":"47","author":"Cron","year":"2020","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2020.06.003_bib0070","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/acr2.11135","article-title":"Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome","volume":"2","author":"Monteagudo","year":"2020","journal-title":"ACR Open Rheumatol."}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X2030142X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X2030142X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:01:51Z","timestamp":1761663711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X2030142X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":7,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1699258X2030142X"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2020.06.003","relation":{},"ISSN":["1699-258X"],"issn-type":[{"type":"print","value":"1699-258X"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anakinra, una alternativa potencial en el tratamiento de la infecci\u00f3n respiratoria grave por SARS-CoV-2 refractaria a tocilizumab","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2020.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}